Aveo Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AVEO PHARMS, and when can generic versions of AVEO PHARMS drugs launch?
AVEO PHARMS has one approved drug.
There are two US patents protecting AVEO PHARMS drugs.
There are forty-three patent family members on AVEO PHARMS drugs in twenty-four countries and eleven supplementary protection certificates in ten countries.
Summary for Aveo Pharms
| International Patents: | 43 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Aveo Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aveo Pharms | FOTIVDA | tivozanib hydrochloride | CAPSULE;ORAL | 212904-002 | Mar 10, 2021 | RX | Yes | Yes | 7,166,722 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Aveo Pharms | FOTIVDA | tivozanib hydrochloride | CAPSULE;ORAL | 212904-001 | Mar 10, 2021 | RX | Yes | No | 6,821,987 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Aveo Pharms | FOTIVDA | tivozanib hydrochloride | CAPSULE;ORAL | 212904-001 | Mar 10, 2021 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
| Aveo Pharms | FOTIVDA | tivozanib hydrochloride | CAPSULE;ORAL | 212904-002 | Mar 10, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Aveo Pharms | FOTIVDA | tivozanib hydrochloride | CAPSULE;ORAL | 212904-002 | Mar 10, 2021 | RX | Yes | Yes | 6,821,987 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Aveo Pharms | FOTIVDA | tivozanib hydrochloride | CAPSULE;ORAL | 212904-001 | Mar 10, 2021 | RX | Yes | No | 7,166,722 | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Aveo Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2003012668 | See Plans and Pricing |
| Portugal | 1559715 | See Plans and Pricing |
| Spain | 2294317 | See Plans and Pricing |
| Brazil | 0209216 | See Plans and Pricing |
| New Zealand | 529046 | See Plans and Pricing |
| Poland | 209822 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Aveo Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1382604 | 122018000018 | Germany | See Plans and Pricing | PRODUCT NAME: TIVOZANIB ODER EIN SALZ ODER SOLVAT HIERVON; REGISTRATION NO/DATE: EU/1/17/1215 20170824 |
| 1382604 | 18C1006 | France | See Plans and Pricing | PRODUCT NAME: TIVOZANIB OU UN DE SES SELS OU DE SES SOLVATES,EN PARTICULIER LE CHLORHYDRATE MONOHYDATE; REGISTRATION NO/DATE: EU/1/17/1215 20170829 |
| 1382604 | 300927 | Netherlands | See Plans and Pricing | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME |
| 1382604 | CR 2018 00007 | Denmark | See Plans and Pricing | PRODUCT NAME: TIVOZANIB ELLER ET SALT ELLER SOLVAT DERAF, SAERLIGT HYDROCHLORIDMONOHYDRATET; REG. NO/DATE: EU/1/17/1215 20170829 |
| 1382604 | 132018000000121 | Italy | See Plans and Pricing | PRODUCT NAME: TIVOZANIB O UN SUO SALE O SOLVATO, IN PARTICOLARE IL CLORIDRATO MONOIDRATO(FOTIVDA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1215, 20170829 |
| 1382604 | 600 | Finland | See Plans and Pricing | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
